GlassScriptPhysician profile
Kimberly Ann Perttu
NPI 1730314253
$1,983.36
in general payments reported to CMS, 2019-2025
21 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.81 · 2021: $332 · 2022: $388 · 2023: $485 · 2024: $458 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $306.82 | 2021-2025 | |
| Astellas Pharma US INC | $245.28 | 2021-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $241.19 | 2023-2025 | |
| Novo Nordisk INC | $211.73 | 2021-2025 | Saxenda, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.87 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $130.37 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Janssen Pharmaceuticals, INC | $91.97 | 2021-2024 | Xarelto |
| Dexcom, INC. | $91.86 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $74.81 | 2022-2024 | Vaxelis, Gardasil 9, Proquad |
| Amgen INC. | $50.43 | 2020-2024 | Prolia, Evenity |
| Sumitomo Pharma America, INC. | $49.40 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $49.14 | 2020-2021 | |
| Myriad Women'S Health, INC. | $43.78 | 2023 | Myrisk |
| Lundbeck LLC | $41.14 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $39.88 | 2024 | Gvoke Hypopen |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $33.44 | 2023 | |
| Organogenesis INC. | $26.80 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.13 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.83 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Perttu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.